Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Celgene Q4 2018 profit beats forecast

Written by: | no-reply@reuters.com | Dated: Thursday, January 31st, 2019

 

Celgene profit beats as psoriasis drug sales surge

 

(Reuters) – Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

Bristol-Myers agreed to buy Celgene for about $74 billion earlier this month, a deal that will expand its pipeline of cancer drugs as the company goes head-to-head against rival Merck & Co.

Sales of Celgene’s biggest drug Revlimid rose 16.5 percent to $2.55 billion in the fourth quarter, in line with analysts’ expectations, according to Refinitiv IBES estimates.

Otezla brought in revenue of $448 million in the quarter, about 21 percent higher than last year and well above the average analyst estimate of $430.2 million.

The drugmaker, which also reaffirmed its forecast for 2020, posted a net profit of $1.07 billion, or $1.50 per share, for the three months ended Dec. 31, compared with a loss of $81 million, or 10 cents per share, a year earlier, when it took a $1.21 billion charge related to the U.S. tax law overhaul.

Excluding one-time items, Celgene earned $2.39 per share, above estimates of $2.32 per share.

Total revenue rose nearly 16 percent to $4.04 billion, higher than the $3.99 billion analysts had expected.

 

Reporting by Manogna Maddipatla and Tamara Mathias in Bengaluru; Editing by Saumyadeb Chakrabarty and Anil D’Silva

 

Reuters source:

https://www.reuters.com/article/us-celgene-results/celgene-profit-beats-as-psoriasis-drug-sales-surge-idUSKCN1PP1NO

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom